RATINGS CHANGES

Ball (BLL - Get Report) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: BLL.

Bristol-Myers Squibb (BMY - Get Report) was downgraded to neutral at Credit Suisse. $63 price target. Opdivo clinical failure for lung cancer was stunning, Credit Suisse said. 

Dominion Resources (D - Get Report) was downgraded to equal-weight from overweight at Morgan Stanley. The valuation is less attractive, based on a $79 price target, Morgan Stanley said. 

FirstEnergy (FE - Get Report) was upgraded to overweight from equal-weight at Morgan Stanley. $41 price target. The valuation is more attractive, as the stock has lagged its peers by 12% year-to-date, Morgan Stanley said. 

21st Century Fox (FOXA) was downgraded to equal-weight from overweight at Barclays. $29 price target. The company was also removed from the Top Picks list, given a lack of near-term catalysts, Barclays said. 

JPMorgan (JPM - Get Report) was downgraded to neutral at Citigroup. $65 price target. The valuation is less attractive, as forward consensus estimates appear too high, Citi said. 

Merck (MRK - Get Report) was upgraded to outperform at Credit Suisse. $73 price target. Keytruda stands to benefit from recent setback for Opdivo, Credit Suisse said. 

Take-Two Interactive (TTWO - Get Report) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: TTWO.

Valley Nation (VLY - Get Report) was downgraded to neutral from overweight at Piper Jaffray. $9.50 price target. The company is facing higher costs, which is holding down margin expansion, Piper said. 

Weyerhaeuser (WY - Get Report) was downgraded to neutral from buy at DA Davidson. The valuation is less attractive, based on a $33 price target, Davidson said.

This article was written by a staff member of TheStreet.